Merck & Co., Inc. MRK

Moderna’s rally has priced in unrealistic expectations for its cancer drug sales.

Moderna falls after Citi downgrades shares to Sell from Hold, saying its recent rally has gone too far.

Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn’t enough to justify the valuation.

After nearly quadrupling over the past month, it's time to get out of Moderna stock, a Citi analyst said Wednesday as he downgraded shares.

Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 holding became about $15,220. Over that period, J&J’s revenue growth accelerated even as the company navigated the anticipated loss of exclusivity and biosimilar erosion for STELARA. If that shift showed up in J&J's calls and filings first, a reader could have spotted it early. So was J&J's run in plain sight before it began.

Merck & Co Inc. (NYSE:MRK) on Wednesday presented initial results from its Phase 2b MK-7240-012 trial at the European Academy of Dermatology and Venereology (EADV) 2026 Congress. Phase 2b Trial Delivers Positive Results The study evaluated tulisokibart—an investigational monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A)—in patients with moderate to severe hidradenitis suppurativa. The trial met its primary endpoint of Hidradenitis Suppurativa Clinical Response 50 (HiSCR

Pfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.

Moderna stock has rallied since the company unveiled clinical updates to its cancer vaccine in collaboration with Merck in late August.

Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 call, management looked past its best-selling drug to newer ones. So what is Merck stock's biggest opportunity from here.

Citigroup just slapped a Sell rating on one of 2026's most explosive biotech stocks, warning that soaring investor hopes around a cancer vaccine partnership with Merck have carried the valuation into dangerous territory.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

RAHWAY, N.J., September 30, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from MK-7240-012, a Phase 2b multicenter, randomized, double-blind, placebo-controlled trial evaluating tulisokibart, an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderate to severe hidradenitis suppurativa (HS). These data will be presented in a Late-Breaking News

Summit Therapeutics stock jumped Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.